Antiphospholipid Antibodies and Early Severe Preeclampsia.

This study is not yet open for participant recruitment. (see Contacts and Locations)
Verified January 2015 by Saint Thomas Hospital, Panama
Information provided by (Responsible Party):
Osvaldo A. Reyes T., Saint Thomas Hospital, Panama Identifier:
First received: February 19, 2012
Last updated: January 1, 2015
Last verified: January 2015
The Antiphospholipid Syndrome is an immune disease where the presence of antibodies directed against cell membrane phospholipids (antiphospholipid antibodies) can cause an hypercoagulable state that causes thrombosis and obstetric complications (miscarriages, stillbirths). Since 1999 the Sapporo Criteria for Antiphospholipid Syndrome diagnosis includes the development of severe preeclampsia before 34 weeks of gestation, but this was done without solid evidence of a relation between the two. Our study will try to add information to this particular point.

Severe Preeclampsia
Antiphospholipid Syndrome

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Prospective
Official Title: Antiphospholipid Antibodies and Early Severe Preeclampsia (< 34 Weeks of Gestation). A Case-Control Study.

Resource links provided by NLM:

Further study details as provided by Saint Thomas Hospital, Panama:

Primary Outcome Measures:
  • Lupus anticoagulant [ Time Frame: 15 months ] [ Designated as safety issue: No ]
    Number of cases positive for Lupus Anticoagulant.

  • Anticardiolipin antibodies [ Time Frame: 15 months ] [ Designated as safety issue: No ]
    Number of cases with high/medium levels of IgG/IgM of anticardiolipin antibodies.

  • B2 Glycoprotein I [ Time Frame: 15 months ] [ Designated as safety issue: No ]
    Number of cases with levels of B2 Glycoprotein 1 > 99%

Estimated Enrollment: 310
Study Start Date: June 2015
Estimated Study Completion Date: August 2016
Estimated Primary Completion Date: July 2016 (Final data collection date for primary outcome measure)
Cases-Early Severe Preeclampsia
Patients with severe preeclampsia before 34 weeks of gestation
Patients with normal pregnancies at term.


Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Pregnant patients admitted for severe preeclampsia between 24-34 weeks pf gestation (cases) and normal patients in labor at term (controls).

Inclusion Criteria:

  • Gestational age between 24-34 weeks
  • Diagnosis of severe preeclampsia

Exclusion Criteria:

  • Known antiphospholipid syndrome.
  • Known presence of antiphospholipid antibodies.
  • Patients with systemic lupus erythematosus.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01538121

Saint Thomas Maternity Hospital
Panama, Panama
Sponsors and Collaborators
Saint Thomas Hospital, Panama
Principal Investigator: Osvaldo A Reyes, MD Saint Thomas Hospital, Panama
  More Information

No publications provided

Responsible Party: Osvaldo A. Reyes T., MD, Saint Thomas Hospital, Panama Identifier: NCT01538121     History of Changes
Other Study ID Numbers: MHST2012-01A
Study First Received: February 19, 2012
Last Updated: January 1, 2015
Health Authority: Panama: Ministry of Health

Keywords provided by Saint Thomas Hospital, Panama:
Antibodies, anticardiolipin
Antibodies, B2 Glycoprotein I
Lupus Anticoagulant
Severe Preeclampsia

Additional relevant MeSH terms:
Antiphospholipid Syndrome
Autoimmune Diseases
Hypertension, Pregnancy-Induced
Immune System Diseases
Pregnancy Complications
Antibodies, Antiphospholipid
Immunologic Factors
Pharmacologic Actions
Physiological Effects of Drugs processed this record on December 01, 2015